CX3CR1/CX3CL1 axis negatively controls glioma cell invasion and is modulated by transforming growth factor-beta1

Giuseppe Sciumé, Alessandra Soriani, Mario Piccoli, Luigi Frati, Angela Santoni, Giovanni Bernardini

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The chemokine CX3CL1 is constitutively expressed in the central nervous system by neurons and astrocytes controlling neuronal survival and neurotransmission. In this work, we analyzed the expression and function of the chemokine CX3CL1 and its receptor, CX3CR1, by human glioma cells. We show that both molecules are expressed on the tumor cell plasma membrane and that soluble CX3CL1 accumulates in the culture supernatants, indicating that the chemokine is constitutively released. We found that CX3CR1 is functional, as all the cell lines adhered to immobilized recombinant CX3CL1 and migrated in response to the soluble form of this chemokine. In addition, the blockade of endogenous CX3CL1 function by means of a neutralizing monoclonal antibody markedly delayed tumor cell aggregation and increased their invasiveness. We also show that CX3CL1 expression is potently modulated by the transforming growth factor-beta1 (TGF-beta1), a key regulator of glioma cell invasiveness. Indeed, both the treatment of glioma cells with recombinant TGF-beta1 and the inhibition of its endogenous expression by siRNA showed that TGF-beta1 decreases CX3CL1 mRNA and protein expression. Overall, our results indicate that endogenously expressed CX3CL1 negatively regulates glioma invasion likely by promoting tumor cell aggregation, and that TGF-beta1 inhibition of CX3CL1 expression might contribute to glioma cell invasive properties.

Original languageEnglish
Pages (from-to)701-710
Number of pages10
JournalNeuro-Oncology
Volume12
Issue number7
DOIs
Publication statusPublished - Jul 2010

Fingerprint

Transforming Growth Factor beta1
Glioma
Chemokine CX3CL1
Cell Aggregation
Chemokines
Cell Membrane
Neoplasms
Neutralizing Antibodies
Synaptic Transmission
Astrocytes
Small Interfering RNA
Central Nervous System
Monoclonal Antibodies
Neurons
Cell Line
Messenger RNA
Proteins

Keywords

  • CX3CL1
  • CX3CR1
  • Glioma
  • Invasion
  • TGF-beta1

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Clinical Neurology

Cite this

CX3CR1/CX3CL1 axis negatively controls glioma cell invasion and is modulated by transforming growth factor-beta1. / Sciumé, Giuseppe; Soriani, Alessandra; Piccoli, Mario; Frati, Luigi; Santoni, Angela; Bernardini, Giovanni.

In: Neuro-Oncology, Vol. 12, No. 7, 07.2010, p. 701-710.

Research output: Contribution to journalArticle

Sciumé, Giuseppe ; Soriani, Alessandra ; Piccoli, Mario ; Frati, Luigi ; Santoni, Angela ; Bernardini, Giovanni. / CX3CR1/CX3CL1 axis negatively controls glioma cell invasion and is modulated by transforming growth factor-beta1. In: Neuro-Oncology. 2010 ; Vol. 12, No. 7. pp. 701-710.
@article{d3c03279d97342ab9c9c4fa745785497,
title = "CX3CR1/CX3CL1 axis negatively controls glioma cell invasion and is modulated by transforming growth factor-beta1",
abstract = "The chemokine CX3CL1 is constitutively expressed in the central nervous system by neurons and astrocytes controlling neuronal survival and neurotransmission. In this work, we analyzed the expression and function of the chemokine CX3CL1 and its receptor, CX3CR1, by human glioma cells. We show that both molecules are expressed on the tumor cell plasma membrane and that soluble CX3CL1 accumulates in the culture supernatants, indicating that the chemokine is constitutively released. We found that CX3CR1 is functional, as all the cell lines adhered to immobilized recombinant CX3CL1 and migrated in response to the soluble form of this chemokine. In addition, the blockade of endogenous CX3CL1 function by means of a neutralizing monoclonal antibody markedly delayed tumor cell aggregation and increased their invasiveness. We also show that CX3CL1 expression is potently modulated by the transforming growth factor-beta1 (TGF-beta1), a key regulator of glioma cell invasiveness. Indeed, both the treatment of glioma cells with recombinant TGF-beta1 and the inhibition of its endogenous expression by siRNA showed that TGF-beta1 decreases CX3CL1 mRNA and protein expression. Overall, our results indicate that endogenously expressed CX3CL1 negatively regulates glioma invasion likely by promoting tumor cell aggregation, and that TGF-beta1 inhibition of CX3CL1 expression might contribute to glioma cell invasive properties.",
keywords = "CX3CL1, CX3CR1, Glioma, Invasion, TGF-beta1",
author = "Giuseppe Scium{\'e} and Alessandra Soriani and Mario Piccoli and Luigi Frati and Angela Santoni and Giovanni Bernardini",
year = "2010",
month = "7",
doi = "10.1093/neuonc/nop076",
language = "English",
volume = "12",
pages = "701--710",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - CX3CR1/CX3CL1 axis negatively controls glioma cell invasion and is modulated by transforming growth factor-beta1

AU - Sciumé, Giuseppe

AU - Soriani, Alessandra

AU - Piccoli, Mario

AU - Frati, Luigi

AU - Santoni, Angela

AU - Bernardini, Giovanni

PY - 2010/7

Y1 - 2010/7

N2 - The chemokine CX3CL1 is constitutively expressed in the central nervous system by neurons and astrocytes controlling neuronal survival and neurotransmission. In this work, we analyzed the expression and function of the chemokine CX3CL1 and its receptor, CX3CR1, by human glioma cells. We show that both molecules are expressed on the tumor cell plasma membrane and that soluble CX3CL1 accumulates in the culture supernatants, indicating that the chemokine is constitutively released. We found that CX3CR1 is functional, as all the cell lines adhered to immobilized recombinant CX3CL1 and migrated in response to the soluble form of this chemokine. In addition, the blockade of endogenous CX3CL1 function by means of a neutralizing monoclonal antibody markedly delayed tumor cell aggregation and increased their invasiveness. We also show that CX3CL1 expression is potently modulated by the transforming growth factor-beta1 (TGF-beta1), a key regulator of glioma cell invasiveness. Indeed, both the treatment of glioma cells with recombinant TGF-beta1 and the inhibition of its endogenous expression by siRNA showed that TGF-beta1 decreases CX3CL1 mRNA and protein expression. Overall, our results indicate that endogenously expressed CX3CL1 negatively regulates glioma invasion likely by promoting tumor cell aggregation, and that TGF-beta1 inhibition of CX3CL1 expression might contribute to glioma cell invasive properties.

AB - The chemokine CX3CL1 is constitutively expressed in the central nervous system by neurons and astrocytes controlling neuronal survival and neurotransmission. In this work, we analyzed the expression and function of the chemokine CX3CL1 and its receptor, CX3CR1, by human glioma cells. We show that both molecules are expressed on the tumor cell plasma membrane and that soluble CX3CL1 accumulates in the culture supernatants, indicating that the chemokine is constitutively released. We found that CX3CR1 is functional, as all the cell lines adhered to immobilized recombinant CX3CL1 and migrated in response to the soluble form of this chemokine. In addition, the blockade of endogenous CX3CL1 function by means of a neutralizing monoclonal antibody markedly delayed tumor cell aggregation and increased their invasiveness. We also show that CX3CL1 expression is potently modulated by the transforming growth factor-beta1 (TGF-beta1), a key regulator of glioma cell invasiveness. Indeed, both the treatment of glioma cells with recombinant TGF-beta1 and the inhibition of its endogenous expression by siRNA showed that TGF-beta1 decreases CX3CL1 mRNA and protein expression. Overall, our results indicate that endogenously expressed CX3CL1 negatively regulates glioma invasion likely by promoting tumor cell aggregation, and that TGF-beta1 inhibition of CX3CL1 expression might contribute to glioma cell invasive properties.

KW - CX3CL1

KW - CX3CR1

KW - Glioma

KW - Invasion

KW - TGF-beta1

UR - http://www.scopus.com/inward/record.url?scp=78650290339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650290339&partnerID=8YFLogxK

U2 - 10.1093/neuonc/nop076

DO - 10.1093/neuonc/nop076

M3 - Article

VL - 12

SP - 701

EP - 710

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 7

ER -